1 in 5 people with chronic hepatitis B are cured in new drug trial.
Bepirovirsen leads to functional cure in one fifth of people with long-term hepatitis B
One in five people with chronic (long term) hepatitis B who were treated with the investigational agent bepirovirsen were functionally cured and no longer needed to take daily antiviral therapy, accor...
www.aidsmap.com
June 4, 2026 at 9:07 AM
1 in 5 people with chronic hepatitis B are cured in new drug trial.
Quellen zu Hepatitis B/Heilungschancen
Süddeutsche Zeitung:
www.sueddeutsche.de/gesundheit/h...
Wiss. Paper:
www.nejm.org/doi/full/10....
Süddeutsche Zeitung:
www.sueddeutsche.de/gesundheit/h...
Wiss. Paper:
www.nejm.org/doi/full/10....
Medizin: Erstmals Heilung von chronischer Hepatitis B möglich
Studien zeigen, dass eine Kombinationstherapie mit Bepirovirsen bei chronischer Hepatitis B funktionelle Heilung bei 20 Prozent der Patienten erreicht.
www.sueddeutsche.de
June 1, 2026 at 8:21 PM
Quellen zu Hepatitis B/Heilungschancen
Süddeutsche Zeitung:
www.sueddeutsche.de/gesundheit/h...
Wiss. Paper:
www.nejm.org/doi/full/10....
Süddeutsche Zeitung:
www.sueddeutsche.de/gesundheit/h...
Wiss. Paper:
www.nejm.org/doi/full/10....
Yes! Journal club!
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the B-Well 1 and B-Well 2 trials investigating bepirovirsen therapy for chronic hepatitis B virus infection. Read the full study for free: https://nej.md/DrG45
#hepatology
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the B-Well 1 and B-Well 2 trials investigating bepirovirsen therapy for chronic hepatitis B virus infection. Read the full study for free: https://nej.md/DrG45
#hepatology
July 21, 2026 at 7:18 PM
Yes! Journal club!
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the B-Well 1 and B-Well 2 trials investigating bepirovirsen therapy for chronic hepatitis B virus infection. Read the full study for free: https://nej.md/DrG45
#hepatology
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the B-Well 1 and B-Well 2 trials investigating bepirovirsen therapy for chronic hepatitis B virus infection. Read the full study for free: https://nej.md/DrG45
#hepatology
GSK put out a teaser regarding Phase 3 clinical trial results of its candidate drug bepirovirsen. They came that a significant proportion of participants who received the drug alongside other antiviral achieved functional cure. I look forward to seeing the data.
www.science.org/content/arti...
www.science.org/content/arti...
New hepatitis B drug could help ‘functionally cure’ some patients
Scientists welcome GSK announcement that two trials succeeded—even though data are still lacking
www.science.org
January 12, 2026 at 5:50 PM
GSK put out a teaser regarding Phase 3 clinical trial results of its candidate drug bepirovirsen. They came that a significant proportion of participants who received the drug alongside other antiviral achieved functional cure. I look forward to seeing the data.
www.science.org/content/arti...
www.science.org/content/arti...
Hoffnung bei chronischer #HepatitisB: Eine neue Kombinationstherapie ermöglicht nun erstmals eine funktionelle Heilung. Für Markus Cornberg @ciim-hannover.bsky.social ein sehr bedeutender Schritt. Für die #SüddeutscheZeitung ordnet er die betreffenden Studien ein. www.sueddeutsche.de/gesundheit/h...
Medizin: Erstmals Heilung von chronischer Hepatitis B möglich
Studien zeigen, dass eine Kombinationstherapie mit Bepirovirsen bei chronischer Hepatitis B funktionelle Heilung bei 20 Prozent der Patienten erreicht.
www.sueddeutsche.de
June 3, 2026 at 7:45 AM
Hoffnung bei chronischer #HepatitisB: Eine neue Kombinationstherapie ermöglicht nun erstmals eine funktionelle Heilung. Für Markus Cornberg @ciim-hannover.bsky.social ein sehr bedeutender Schritt. Für die #SüddeutscheZeitung ordnet er die betreffenden Studien ein. www.sueddeutsche.de/gesundheit/h...
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said. on.wsj.com/3RyyGfQ
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
on.wsj.com
May 28, 2026 at 9:01 AM
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said. on.wsj.com/3RyyGfQ
“In a paper published in the New England Journal of Medicine, the investigators reported that about 20 percent of patients who got bepirovirsen saw a functional cure: No virus could be found 48 weeks after the treatment ended. No one who received the placebo was cured.”
Scientists Find a Potential Cure for Chronic Hepatitis B
www.nytimes.com
May 28, 2026 at 12:06 PM
“In a paper published in the New England Journal of Medicine, the investigators reported that about 20 percent of patients who got bepirovirsen saw a functional cure: No virus could be found 48 weeks after the treatment ended. No one who received the placebo was cured.”
HBsAg loss & seroconversion in HBeAg- chronic hep B subjects on NA Tx after AHB-137 Tx: preliminary data, multicenter, rando, open-label phase 2a #TLM24
w24 (EOT, on going)
• HBsAg ⬇️ 78% >3log10
• HBsAg loss 69%(!)
*My take: AHB-137= better Bepirovirsen (ASO)?
To be continued 😮
#Liversky #IDsky
w24 (EOT, on going)
• HBsAg ⬇️ 78% >3log10
• HBsAg loss 69%(!)
*My take: AHB-137= better Bepirovirsen (ASO)?
To be continued 😮
#Liversky #IDsky
November 21, 2024 at 2:47 AM
Is a cure for HBV on the horizon?
In phase 3 trials, 20% of people on bepirovirsen had a functional cure of HBV compared to none in placebo group. Elevated ALT was the most common SAE.
www.nejm.org/doi/full/10.... #IDSky
In phase 3 trials, 20% of people on bepirovirsen had a functional cure of HBV compared to none in placebo group. Elevated ALT was the most common SAE.
www.nejm.org/doi/full/10.... #IDSky
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection | NEJM
Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus
(HBV) transcripts, has the potential to result in a functional cure, defined by at
least 24 weeks of a sustaine...
www.nejm.org
May 28, 2026 at 2:39 PM
Is a cure for HBV on the horizon?
In phase 3 trials, 20% of people on bepirovirsen had a functional cure of HBV compared to none in placebo group. Elevated ALT was the most common SAE.
www.nejm.org/doi/full/10.... #IDSky
In phase 3 trials, 20% of people on bepirovirsen had a functional cure of HBV compared to none in placebo group. Elevated ALT was the most common SAE.
www.nejm.org/doi/full/10.... #IDSky
Erstmals könnte chronische Hepatitis B heilbar werden: GSK-Wirkstoff Bepirovirsen besteht Phase III. FDA entscheidet bis 26. Oktober 2026. 300 Millionen Menschen warten.
Bepirovirsen: Erstes Mittel zur Hepatitis-B-Heilung
Chronische Hepatitis B infiziert 300 Millionen Menschen weltweit. Bisherige Therapien heilen nicht. Mit Bepirovirsen hat GSK nun ein Mittel in Phase-III-Studien erprobt, das erstmals eine dauerhafte funktionelle Heilung ermöglicht. Die FDA hat die Zu
denkstrom.org
August 19, 2026 at 4:17 PM
Erstmals könnte chronische Hepatitis B heilbar werden: GSK-Wirkstoff Bepirovirsen besteht Phase III. FDA entscheidet bis 26. Oktober 2026. 300 Millionen Menschen warten.
Hépatite B : vers une guérison fonctionelle (enfin) possible ?
Le bepirovirsen, annoncé par GSK, ouvre une piste inédite après des décennies d’impasse thérapeutique. Prometteur, mais encore entouré d’incertitudes.
La rédaction de Remaides vous dit tout : www.aides.org/actualite/la...
Le bepirovirsen, annoncé par GSK, ouvre une piste inédite après des décennies d’impasse thérapeutique. Prometteur, mais encore entouré d’incertitudes.
La rédaction de Remaides vous dit tout : www.aides.org/actualite/la...
L'Actu vue par Remaides : Hépatite B : un nouveau traitement relance l’espoir d’une guérison fonctionnelle
Annoncé par le géant pharmaceutique GSK, le bepirovirsen ouvre une piste inédite dans le traitement de l’hépatite B chronique, longtemps considérée comme incurable. Si les premiers résultats d’essais ...
www.aides.org
January 30, 2026 at 7:37 AM
Hépatite B : vers une guérison fonctionelle (enfin) possible ?
Le bepirovirsen, annoncé par GSK, ouvre une piste inédite après des décennies d’impasse thérapeutique. Prometteur, mais encore entouré d’incertitudes.
La rédaction de Remaides vous dit tout : www.aides.org/actualite/la...
Le bepirovirsen, annoncé par GSK, ouvre une piste inédite après des décennies d’impasse thérapeutique. Prometteur, mais encore entouré d’incertitudes.
La rédaction de Remaides vous dit tout : www.aides.org/actualite/la...
Als erstes Land weltweit hat #Japan das Medikament Hibsago (Wirkstoff: #Bepirovirsen) gegen chronische #HepatitisB zugelassen. In fast 20% aller Fälle konnte das Medikament in Phase-III-Studien eine funktionelle Heilung erreichen (verglichen mit etwa 1% bei den bisher verfügbaren Medikamenten). /2
August 24, 2026 at 4:01 PM
Als erstes Land weltweit hat #Japan das Medikament Hibsago (Wirkstoff: #Bepirovirsen) gegen chronische #HepatitisB zugelassen. In fast 20% aller Fälle konnte das Medikament in Phase-III-Studien eine funktionelle Heilung erreichen (verglichen mit etwa 1% bei den bisher verfügbaren Medikamenten). /2
Erstmals könnte chronische Hepatitis B heilbar werden: GSK-Wirkstoff Bepirovirsen besteht Phase III. FDA entscheidet bis 26. Oktober 2026. 300 Millionen Menschen warten.
Bepirovirsen: Erstes Mittel zur Hepatitis-B-Heilung
Chronische Hepatitis B infiziert 300 Millionen Menschen weltweit. Bisherige Therapien heilen nicht. Mit Bepirovirsen hat GSK nun ein Mittel in Phase-III-Studien erprobt, das erstmals eine dauerhafte funktionelle Heilung ermöglicht. Die FDA hat die Zu
denkstrom.org
May 22, 2026 at 8:02 AM
Erstmals könnte chronische Hepatitis B heilbar werden: GSK-Wirkstoff Bepirovirsen besteht Phase III. FDA entscheidet bis 26. Oktober 2026. 300 Millionen Menschen warten.
Bepirovirsen: la nuova frontiera della cura dell’epatite B
Per la prima volta una terapia ha mostrato la possibilità di ottenere la guarigione funzionale in alcuni pazienti con epatite B cronica.
www.innlifes.com/biotech/come...
Per la prima volta una terapia ha mostrato la possibilità di ottenere la guarigione funzionale in alcuni pazienti con epatite B cronica.
www.innlifes.com/biotech/come...
Bepirovirsen: la nuova frontiera della cura dell’epatite B
Bepirovirsen apre nuove prospettive per l’epatite B cronica: ne abbiamo parlato con il professor Pietro Lampertico, tra gli autori dello studio.
www.innlifes.com
September 3, 2026 at 5:00 AM
Bepirovirsen: la nuova frontiera della cura dell’epatite B
Per la prima volta una terapia ha mostrato la possibilità di ottenere la guarigione funzionale in alcuni pazienti con epatite B cronica.
www.innlifes.com/biotech/come...
Per la prima volta una terapia ha mostrato la possibilità di ottenere la guarigione funzionale in alcuni pazienti con epatite B cronica.
www.innlifes.com/biotech/come...
B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. https://nej.md/4fKe9ib
#EASL
#EASL
May 28, 2026 at 8:35 AM
B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. https://nej.md/4fKe9ib
#EASL
#EASL
B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results: https://nej.md/4fKe9ib
June 28, 2026 at 4:01 PM
B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results: https://nej.md/4fKe9ib
HBV Functional cure with Bepirovirsen
B-Well 1 and B-Well 2 phase 3 studies
➡️ 24 weeks of Bepi s/c q1 week (all on NUCs)
~19% if qHBsAg <3000
~26% if qHBsAg <1000
#EASL2026 #IDsky
B-Well 1 and B-Well 2 phase 3 studies
➡️ 24 weeks of Bepi s/c q1 week (all on NUCs)
~19% if qHBsAg <3000
~26% if qHBsAg <1000
#EASL2026 #IDsky
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection | NEJM
Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustaine...
www.nejm.org
May 28, 2026 at 12:21 PM
Bepirovirsen Achieves Functional Cure in 20% of Chronic HBV Patients After 72 Weeks, Outpacing Placebo in Phase 3 Trials
by Hou J, Lim SG (...) Elston R et 45 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2515131
by Hou J, Lim SG (...) Elston R et 45 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2515131
June 6, 2026 at 2:06 PM
Bepirovirsen Achieves Functional Cure in 20% of Chronic HBV Patients After 72 Weeks, Outpacing Placebo in Phase 3 Trials
by Hou J, Lim SG (...) Elston R et 45 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2515131
by Hou J, Lim SG (...) Elston R et 45 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2515131
Science: New hepatitis B drug could help ‘functionally cure’ some patients
bepirovirsen
bit.ly/4pRpoqR by @cohenjon.bsky.social @science.org
bepirovirsen
bit.ly/4pRpoqR by @cohenjon.bsky.social @science.org
January 10, 2026 at 8:20 PM
Science: New hepatitis B drug could help ‘functionally cure’ some patients
bepirovirsen
bit.ly/4pRpoqR by @cohenjon.bsky.social @science.org
bepirovirsen
bit.ly/4pRpoqR by @cohenjon.bsky.social @science.org
On IDSA's & HIVMA's Science Speaks blog: Two Phase 3 trials reported in the New England Journal of Medicine assessed bepirovirsen for the treatment for chronic hepatitis B virus infection. Read IDSA's Journal Club review by Erica Kaufman West, MD, FIDSA. https://bit.ly/4wuqkEF
“B” is for “belief”: Bepirovirsen brings hope for an HBV cure
Two Phase 3 trials assessed bepirovirsen for the treatment for chronic hepatitis B virus infection.
bit.ly
August 18, 2026 at 12:00 AM
On IDSA's & HIVMA's Science Speaks blog: Two Phase 3 trials reported in the New England Journal of Medicine assessed bepirovirsen for the treatment for chronic hepatitis B virus infection. Read IDSA's Journal Club review by Erica Kaufman West, MD, FIDSA. https://bit.ly/4wuqkEF
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection | New England Journal of Medicine www.nejm.org/doi/full/10....
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection | NEJM
Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustaine...
www.nejm.org
June 4, 2026 at 8:56 PM
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection | New England Journal of Medicine www.nejm.org/doi/full/10....
New insights into Hepatitis B and Delta show biomarkers improving diagnosis.
Therapies like Bepirovirsen aim for a functional cure by lowering viral antigens and restoring immune response to achieve HBsAg loss.
www.youtube.com/watch?v=_2Tj...
Therapies like Bepirovirsen aim for a functional cure by lowering viral antigens and restoring immune response to achieve HBsAg loss.
www.youtube.com/watch?v=_2Tj...
Update Novel Biomarkers and Compounds in HBV/HDV - Valentina Svicher
YouTube video by Academic Medical Education
www.youtube.com
July 13, 2025 at 8:34 PM
New insights into Hepatitis B and Delta show biomarkers improving diagnosis.
Therapies like Bepirovirsen aim for a functional cure by lowering viral antigens and restoring immune response to achieve HBsAg loss.
www.youtube.com/watch?v=_2Tj...
Therapies like Bepirovirsen aim for a functional cure by lowering viral antigens and restoring immune response to achieve HBsAg loss.
www.youtube.com/watch?v=_2Tj...
New in the June 25, 2026, issue of NEJM:
Bepirovirsen for Chronic Hepatitis B Virus Infection (B-Well 1 and B-Well 2 trials) nej.md/4fKe9ib
Pulsed Field Ablation for Atrial Fibrillation (AVANT GUARD trial) nej.md/3QnSpya
Bepirovirsen for Chronic Hepatitis B Virus Infection (B-Well 1 and B-Well 2 trials) nej.md/4fKe9ib
Pulsed Field Ablation for Atrial Fibrillation (AVANT GUARD trial) nej.md/3QnSpya
June 25, 2026 at 1:01 PM
New in the June 25, 2026, issue of NEJM:
Bepirovirsen for Chronic Hepatitis B Virus Infection (B-Well 1 and B-Well 2 trials) nej.md/4fKe9ib
Pulsed Field Ablation for Atrial Fibrillation (AVANT GUARD trial) nej.md/3QnSpya
Bepirovirsen for Chronic Hepatitis B Virus Infection (B-Well 1 and B-Well 2 trials) nej.md/4fKe9ib
Pulsed Field Ablation for Atrial Fibrillation (AVANT GUARD trial) nej.md/3QnSpya
Results from a clinical trial report that a new drug achieved a functional cure in approximately one in five patients with chronic hepatitis B. www.optimistdaily.com/2026/06/a-ne...
A new drug just cleared hepatitis B in 1 in 5 patients | The Optimist Daily
A phase III trial found bepirovirsen achieved functional cure in 19 percent of chronic hepatitis B patients, versus 3 percent with standard care.
www.optimistdaily.com
June 1, 2026 at 6:58 PM
Results from a clinical trial report that a new drug achieved a functional cure in approximately one in five patients with chronic hepatitis B. www.optimistdaily.com/2026/06/a-ne...